Cardiovascular disease (CVD) remains the leading cause of mortality globally, necessitating an effective risk assessment strategy. A comprehensive approach is crucial due to the multifactorial nature of CVD, encompassing genetic, environmental and lifestyle factors.
Genetic predisposition plays a significant role in CVD risk. With advancements in genetic testing, identifying high-risk individuals has become more accurate. However, the complexity of genetic interactions and the influence of epigenetic factors necessitate a nuanced approach to interpreting these results.
Environmental determinants such as air pollution and secondhand smoke significantly contribute to CVD risk. Exposure to these factors can lead to oxidative stress and inflammation, promoting atherosclerosis. Therefore, a comprehensive risk assessment should consider the patient's environmental exposures.
Diet, physical inactivity, and tobacco use are major modifiable risk factors for CVD. A comprehensive risk assessment should include a thorough lifestyle evaluation, with emphasis on identifying and addressing these modifiable risk factors.
Recent research has highlighted the role of biomarkers in predicting CVD risk. High-sensitivity C-reactive protein (hs-CRP), Lipoprotein(a), and homocysteine are among the emerging biomarkers. Incorporating these tests into routine risk assessment can provide additional predictive value.
Imaging techniques such as coronary calcium scoring and carotid intima-media thickness measurement have shown promise in improving risk prediction. These non-invasive methods provide direct evidence of subclinical atherosclerosis, thereby enhancing risk stratification.
A comprehensive approach to CVD risk assessment necessitates the integration of genetic, environmental, lifestyle factors, along with novel biomarkers and imaging techniques. Such an approach allows for a more accurate prediction of CVD risk, facilitating early intervention and improved patient outcomes.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation